CASE STUDY: TCGA Data Leveraged for Developing FDA-Designated Breakthrough Therapy
Pharmaceutical company Loxo Oncology used TCGA data in the research that led them to develop FDA-designated Breakthrough Therapy LOXO-101, a promising new targeted therapy.
The Cancer Genome Atlas: More Than a Large Collection of Data
Genomic Contributions to Breast Cancer Disparities
Dr. Tanya Keenan shares her study's findings on the genomic contributions to breast cancer disparities and advocates for inclusion in breast cancer research.
Next-Generation Pathology: TCGA Microscope Slides Helped Train an Automated Lung Cancer Diagnostic Tool
Using over 2,000 pathology slides of lung cancer from The Cancer Genome Atlas (TCGA), researchers from Stanford University trained a machine-learning pipeline to create the first computational model that analyzes image features to better predict patient outcomes.
- July 2016
Longitudinal Study Charts Brain Tumor Evolution
Scientists analyzed the genomes of 114 glioblastoma tumors at the time of diagnosis and at the time of recurrence, including recurrent tumors from The Cancer Genome Atlas. The study found that the relapsed tumors likely arose years before the initial diagnosis, highlighting the complexity of glioblastoma.
- March 2016
Tumor Heterogeneity Influences the Immune System's Ability to Fight Cancer
A new study found that activation of the immune system against cancer depends on the number and variety of mutations in the tumor. The findings provide insight into immune surveillance and suggest that variation, or heterogeneity, within a tumor may be an important predictor of whether patients could benefit from immunotherapy.
- October 2015
Researchers Use TCGA Data for First Pan-Cancer Analyses of RNA-Editing
By comparing A-to-I editing sites in TCGA tumor and matched normal samples, researchers observed elevated levels of A-to-I RNA editing in most cancer types, indicating that RNA editing contributes to the diversity of the cancer transcriptome.
- September 2015
DNA Methylation Inhibitor Triggers Anti-Viral Immune Response in Cancer
DNA methyltransferase inhibitors (DNMTis) can trigger an anti-viral immune response that may sensitize cancers to already developed immunotherapies like immune checkpoint therapy.